[A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
Alfuzosin (dalphaz) has been tried in 32 patients with benign prostatic hyperplasia (BPH). The treatment lasted for 14 weeks: 2 weeks of placebo and 12 weeks of alfuzosin. The drug was given in a daily dose of 10 mg (5 mg twice a day). The response was registered in 87.5% of cases. Improvement of urination occurred by all the parameters of IPSS scale (the overall IPSS dropped by 10.5 scores). Dalphaz had a good hypotensive effect: high blood pressure lowered to normal, normal pressure did not change. Dalphaz was well tolerated in all the cases except one when an allergic eruption broke out.
Lopatkin
N A
NA
Perepanova
T S
TS
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D016037:Single-Blind Method; D013607:Tablets; D013997:Time Factors; D014563:Urodynamics / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D013607:Tablets; C047638:alfuzosin